BBlogFlow

PCOS TO PMOS: Why the name matters and what it means now - Stamford Health

·May 19, 2026
Source: Stamford Health
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. Stamford Health

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

How GLP-1 Medications Affect PCOS, Fertility, and Pregnancy - News-Medical

IntroductionPathophysiology of PCOS and reproductive dysfunctionMechanistic rationale for GLP-1 in fertility improvementEffects on metabolic and hormonal parametersEvidence on fertility and pregnancy outcomesPreclinical and translational evidenceSafety and pregnancy considerationsLimitations and research gapsReferences Weight, insulin, and ovarian hormones connect PCOS with infertility, raising questions about where GLP-1 therapies could fit in reproductive care.

News-Medical·

What Is Culinary Medicine? Bridging Nutrition, Cooking, and Health - News-Medical

IntroductionWhy nutrition advice often falls shortWhat is culinary medicine? How cooking skills influence healthCulinary medicine in clinical practiceTeaching future healthcare professionalsChallenges and future directionsConclusions: Bringing nutrition science into everyday practiceReferencesFurther reading What happens when dietary advice becomes a cooking lesson? Teaching kitchens offer a setting to examine how food-preparation skills connect nutrition science to everyday patient care.

News-Medical·

ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function - Psychiatric Times

Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed. According to a new review, attention-deficit/hyperactivity disorder (ADHD) medications may help improve brain fog in perimenopausal women. Investigators underwent a scoping review to better understand the potential of ADHD medications as a novel, targeted therapy to improve executive dysfunction experienced during women’s perimenopause period. They specifically looked at original research studies involving the ADHD medications lisdexamfetamine and atomoxetine, and their effects on cognition and ADHD symptom severity. Inclusion criteria included biological women 45 to 60 years of age with a last menstrual period less than 10 years ago. Exclusion criteria included transgender women, disordered sleep, surgical menopause, primary ovarian insufficiency, premature or early menopause, and previous or current cancer diagnosis. “Many women at perimenopause notice changes in focus, memory, and organization that look a lot like ADHD, and the two can be hard to tell apart.

Psychiatric Times·